Long-term outcome of cadaveric kidney grafts with triple drug therapy.
Amemiya
H
H
National Children's Medical Research Center, Tokyo, Japan.
Suzuki
S
S
Hayashi
R
R
Nakatani
T
T
D002102:Cadaver; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000188:drug therapy; D006085:Graft Survival; D006146:Guanidines / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000401:mortality / Q000502:physiology*; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D012189:Retrospective Studies; D012263:Ribonucleosides / Q000008:administration & dosage / Q000627:therapeutic use; D016019:Survival Analysis; D013997:Time Factors; D014019:Tissue Donors; D016896:Treatment Outcome
D006146:Guanidines; D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine; D016572:Cyclosporine; C037258:gusperimus; D008775:Methylprednisolone